

UNITED STATES INTERNATIONAL TRADE COMMISSION  
Washington, DC 20436

**MEMORANDUM ON PROPOSED TARIFF LEGISLATION  
of the 109<sup>th</sup> Congress<sup>1</sup>**

[Date approved: October 24, 2006]<sup>2</sup>

**Bill No. and sponsor:** S. 3155 (Mr. Barack Obama of Illinois).

**Proponent name, location:** Astellas Pharma U.S., Inc., Deerfield, IL.

**Other bills on product (109<sup>th</sup> Congress only):** None.

**Nature of bill:** Temporary duty suspension through December 31, 2009.

**Retroactive effect:** None.

**Suggested article description(s) for enactment (including appropriate HTS subheading(s)):**

3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-,hydrochloride, (3R) (CAS No. 748810-28-8) (provided for in subheading 2933.99.53).

**Check one:**  Same as that in bill as introduced.  
 Different from that in bill as introduced (see Technical comments section).

**Product information, including uses/applications and source(s) of imports:**

3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-,hydrochloride, (3R) is a synthetic organic chemical used as a drug to treat patients with atrial fibrillation and atrial flutter. Astellas imports the product from Switzerland.

**Estimated effect on customs revenue:**

HTS subheading: <u>2933.99.53</u>					
	2006	2007	2008	2009	2010
<del>Col. 1-General rate of duty</del>	6.5%	6.5%	6.5%	6.5%	6.5%
Estimated value <i>dutiable</i> imports	\$3,100,000	\$3,100,000	\$3,100,000	\$3,100,000	\$3,100,000
Customs revenue loss	\$201,500	\$201,500	\$201,500	\$201,500	\$201,500

Source of estimated dutiable import data: Industry estimates.

**Contacts with domestic firms/organizations (including the proponent):**

<sup>1</sup> Industry analyst preparing report: Philip Stone (202-205-3424); Tariff Affairs contact: David Michels (202-205-3440).

<sup>2</sup> Access to an electronic copy of this memorandum is available at [http://usitc.gov/tata/hts/other/rel\\_doc/bill\\_reports/index.htm](http://usitc.gov/tata/hts/other/rel_doc/bill_reports/index.htm).

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
		(Yes/No)		
Astellas Pharma U.S., Inc. (Proponent) Eric Rock, 312-902-5228	07/26/2006	No	No	No
Abbott Claude Burkey, Fax: 202-783-6631	07/27/2006	No	No	No
Bayer Julie Van Egmund, Fax: 202-737-8909	07/27/2006	No	No	No
Bristol Myers Squibb Co. David Warr, Fax: 202-783-2308	07/27/2006	No	No	No
DuPont Helen McMahon, Fax: 302-355-2994	07/27/2006	No	No	No
Gilead Sciences Cheryl Myriad, Fax: 650-522-5853	07/27/2006	No	No	No
Glaxo Wellcome Sara Froehlich, Fax: 202-715-1001	07/27/2006	No	No	No
Interferon Sciences, Inc. Samuel Ronel, Fax: 732-249-6895	07/27/2006	No	No	No
Merck & Co., Inc. Thomas Bombelles, Fax: 202-638-3670	07/27/2006	No	No	No
Niche Pharmaceuticals Steve Brandon, Fax: 817-491-3533	07/27/2006	No	No	No
Novartis Tracy Haller, Fax: 202-628-4763	07/27/2006	No	No	No
Noveon Tom Dirmyer, Fax: 216-447-5720	07/27/2006	No	No	No
Pfizer Katherine Bennett, Fax: 202-347-2044 Philip Ellsworth, Fax: 212-309-5317	07/27/2006	No	No	No
Procter & Gamble Jim McCarthy, Fax: 202-393-4606	07/27/2006	No	No	No
Schering-Plough Rob Lively, Fax: 202-463-8809	07/27/2006	No	No	No
Watson Sarah Sweet, Fax: 951-270-1429	07/27/2006	No	No	No

**Technical comments:**<sup>3</sup>

The Commission suggests that the article description on page 1 of this report be used in the proposed new heading in order to remove company-specific references to the product.

---

<sup>3</sup> The Commission may express an opinion on the HTS classification of a product to facilitate consideration of the bill. However, by law, only the U.S. Customs Service is authorized to issue a binding ruling on this matter. The Commission believes that the U.S. Customs Service should be consulted prior to enactment of the bill.

109<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

# S. 3155

To suspend temporarily the duty on RSD 1235.

---

IN THE SENATE OF THE UNITED STATES

MAY 25, 2006

Mr. OBAMA introduced the following bill; which was read twice and referred to the Committee on Finance

---

## A BILL

To suspend temporarily the duty on RSD 1235.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. RSD 1235.**

4 (a) IN GENERAL.—Subchapter II of chapter 99 of  
5 the Harmonized Tariff Schedule of the United States is  
6 amended by inserting in numerical sequence the following  
7 new heading:

“	9902.28.33	RSD 1235. 3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-hydrochloride, (3R). (CAS No. 748810-28-8) (provided for in subheading 2933.99.53) .....	Free	No change	No change	On or before 12/31/2009	”.
---	------------	--	------	-----------	-----------	-------------------------	----

1       (b) **EFFECTIVE DATE.**—The amendment made by  
2 subsection (a) applies to goods entered, or withdrawn from  
3 warehouse for consumption, on or after the 15th day after  
4 the date of the enactment of this Act.

○